Recognition of modified histones by 'reader' proteins plays a critical role in the regulation of chromatin 1 . H3K36 trimethylation (H3K36me3) is deposited onto the nucleosomes in the transcribed regions after RNA polymerase II elongation. In yeast, this mark in turn recruits epigenetic regulators to reset the chromatin to a relatively repressive state, thus suppressing cryptic transcription 2 . However, much less is known about the role of H3K36me3 in transcription regulation in mammals. This is further complicated by the transcriptioncoupled incorporation of the histone variant H3.3 in gene bodies 3 .
Recognition of modified histones by 'reader' proteins plays a critical role in the regulation of chromatin 1 . H3K36 trimethylation (H3K36me3) is deposited onto the nucleosomes in the transcribed regions after RNA polymerase II elongation. In yeast, this mark in turn recruits epigenetic regulators to reset the chromatin to a relatively repressive state, thus suppressing cryptic transcription 2 . However, much less is known about the role of H3K36me3 in transcription regulation in mammals. This is further complicated by the transcriptioncoupled incorporation of the histone variant H3.3 in gene bodies 3 .
Here we show that the candidate tumour suppressor ZMYND11 specifically recognizes H3K36me3 on H3.3 (H3.3K36me3) and regulates RNA polymerase II elongation. Structural studies show that in addition to the trimethyl-lysine binding by an aromatic cage within the PWWP domain, the H3.3-dependent recognition is mediated by the encapsulation of the H3.3-specific 'Ser 31' residue in a composite pocket formed by the tandem bromo-PWWP domains of ZMYND11.
Chromatin immunoprecipitation followed by sequencing shows a genome-wide co-localization of ZMYND11 with H3K36me3 and H3.3 in gene bodies, and its occupancy requires the pre-deposition of H3.3K36me3. Although ZMYND11 is associated with highly expressed genes, it functions as an unconventional transcription corepressor by modulating RNA polymerase II at the elongation stage. ZMYND11 is critical for the repression of a transcriptional program that is essential for tumour cell growth; low expression levels of ZMYND11 in breast cancer patients correlate with worse prognosis. Consistently, overexpression of ZMYND11 suppresses cancer cell growth in vitro and tumour formation in mice. Together, this study identifies ZMYND11 as an H3.3-specific reader of H3K36me3 that links the histone-variant-mediated transcription elongation control to tumour suppression.
ZMYND11 (also known as BS69) is an adenovirus early region 1A (E1A)-interacting protein that functions as a co-repressor of E1A and cellular transcription factors including the c-Myb and ETS-2 oncoproteins [4] [5] [6] . It contains several histone 'reader' modules, including a plant homeodomain (PHD), a bromodomain and a PWWP domain (Fig. 1a) , indicating a role in chromatin regulation. To determine whether these domains can recognize histone modification(s), we used a histone peptide array (Supplementary Table 1 ) and found that the recombinant PHD-bromo-PWWP (PBP) domains specifically bound H3K36me3 peptides (Fig. 1b) , which was also confirmed by peptide pull-down assays (Fig. 1c) . In addition, ZMYND11 PBP also bound H3K36me3 on bulk histones and the reconstituted H3K36-specific methyl-lysine analogue-containing nucleosomes (Extended Data Fig. 1a, b) . Several PWWP domains can recognize methylation on histones H3K36 or H3K79 (refs 7-9); therefore we asked whether ZMYND11 PWWP alone was able to bind H3K36me3. The results showed that neither the isolated PWWP nor the PHD and bromodomain bound H3K36me3, whereas the tandem bromo-PWWP retained a weak interaction ( Fig. 1d and Extended Data Fig. 1c ). Isothermal titration calorimetry (ITC) showed a dissociation constant (K d ) of 56 mM for PBP and 71 mM for bromo-PWWP to the H3K36me3 peptide, whereas weak or no binding to the di-, mono-and unmethylated H3K36 peptides ( Fig. 1e and Extended Data Fig. 1d ). Furthermore, deletion of the PWWP, bromo or PHD domains greatly diminished full-length ZMYND11 binding to H3K36me3 peptide and chromatin, whereas deletion of the MYND domain had no effect (Extended Data Fig. 1e, f) .
To gain molecular insights into the reader function of ZMYND11, we solved the crystal structure of the tandem bromo-PWWP domain in its free state and in complex with H3K36me3 peptide at 1.95 Å and 2.0 Å , respectively (Extended Data Table 1 and Supplementary Discussion). Successful crystallization of the bromo-PWWP-H3K36me3 complex was facilitated by alanine mutation of D234 and E236 within the bromodomain to disrupt unfavourable packing contacts without affecting protein folding and histone binding (Extended Data Fig. 2a-e) . The tandem bromo-PWWP domain adopts a V-shaped structure imparted by a 'kink' around a previously uncharacterized zinc finger (ZnF) motif (Fig. 1f, g ). Several structural features imply that ZMYND11 bromodomain is unlikely to be a histone acetyl-lysine-binding module (Extended Data Fig. 2f-l) . The PWWP domain adopts a five-bladed b-barrel fold with an extended carboxy (C)-terminal a-helix (a P ), with a conserved H3K36me3-binding aromatic cage 7-9 formed by F291 and W294 of the b1-b2 loop and F310 of the b3-b4 loop ( Fig. 1h and Extended Data Fig. 3a-c) . Alanine mutations abrogated ZMYND11 binding to the H3K36me3 peptide and chromatin without affecting the overall protein folding (Figs 1i, 2i and Extended Data Fig. 3d-f ). Despite extensive interactions observed in crystals for the histone peptide, the relatively weak binding affinity suggests that an alternative binding mechanism is plausible. Indeed, the PWWP domain was previously identified as a DNA-binding motif 10 . Consistent with a recent report 11 , we found that ZMYND11 bromo-PWWP bound to DNA at low micromolar level (Extended Data Fig. 3g ). The higher binding affinity for DNA than that for histone peptides is in agreement with observations for some other PWWP domains 12, 13 . Although not detected in our pull-downs using peptides and oligonucleotides, all these features suggest that a synergy between histone and DNA may contribute to ZMYND11 binding at the nucleosomal level (Supplementary Discussion).
The H3K36me3 peptides used in the biochemical and structural studies were histone H3.3-based peptides (Fig. 2a) . The histone variant H3.3 possesses a signature motif 'S31 … A87AIG90' that is distinct from the 'A31 … S87AVM90' sequence signature of the canonical histone H3.1/2 (ref. 3). Our structure showed that the H3.3-specific 'S31' residue and its neighbouring T32 were encapsulated at the bottom of the 'bromo-ZnF-PWWP' valley ( Fig. 2b) , contributing to the ZMYND11-H3 interactions in addition to the binding of K36me3 by the PWWP aromatic cage. Indeed, the binding of ZMYND11 to H3.3K36me3 was much stronger than its binding to the H3.1 counterpart, with a sevento eightfold difference in binding affinity (Fig. 2c, d and Extended Data Fig. 4a, b) . Furthermore, Flag-tagged histone H3.3, but not H3.1, strongly co-immunoprecipitated ZMYND11 in cells (Extended Data Fig. 4c ). Together, these results indicate that the H3.3-specific S31 residue is indispensable for ZMYND11-H3K36me3 interaction.
We also solved the structure of ZMYND11 bromo-PWWP-H3.1K36me3 complex at 2.3 Å for comparison (Extended Data Table 1 and Extended Data Fig. 4d ). Several hydrogen-bonding interactions around the 'A29-G33' segment in the bromo-PWWP-H3.3 complex were lost in the bromo-PWWP-H3.1 complex after the 'Ser to Ala' conversion at position 31 ( Fig. 2e, f and Extended data Fig. 4e, f) . Superimposition of the complex structures showed a conformational adjustment of the H3.1 'A29-G33' segment ( Fig. 2e) , indicating a non-ideal encapsulation. As highlighted in the LIGPLOT diagram 14 , eight direct hydrogen bonds and two sets of water-mediated hydrogen bonding were detected upon H3.3 variant binding (Fig. 2g) , whereas only three direct hydrogen bonds and two sets of water-mediated hydrogen bonding were observed for H3.1 recognition (Fig. 2h) . Notably, residues from all three modules, bromo, ZnF and PWWP, contributed to the A29-G33 segment recognition through the formation of a composite pocket, calling attention to the theme of 'module integration' for extended reader function 15 . Unique hydrogenbonding interactions for the H3.3-specific readout were particularly supplied by 'R168-A29', 'E251-S31', 'E254-T32' and 'N266-S31' of the ZMYND11-H3.3 pair along with an adaptive flipping of the R168 side chain (Fig. 2e, g ), and mutations diminished the bindings ( Fig. 2i and Extended Data Fig. 4g ). Together, the results strongly support a role of ZMYND11 as an H3.3-specific reader of H3K36me3. We next sought to determine whether ZMYND11 co-localizes with H3K36me3 and the H3.3 variant in the genome by chromatin immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) analysis. We identified 9,759 ZMYND11 peaks distributed in 3,353 genes in human osteosarcoma U2OS cells (Supplementary Table 2 ). The peaks were highly enriched in introns and exons (herein defined as the gene body) but not promoters (Fig. 3a) . Strikingly, the average distribution of all ZMYND11-bound peaks recapitulated the genomic distribution of H3K36me3 (ref. 16) (Fig. 3b and Supplementary Table 3): absent from the transcription start site (TSS), but gradually increasing in the gene body towards the 39 end and peaking at the transcription termination site (TTS).
We also determined the genome-wide distribution of histone variant H3.3 by ChIP-seq analysis of Flag-H3.3 stably expressed in U2OS cells (Extended Data Fig. 5a and Supplementary Table 4). In accordance with previous observations [17] [18] [19] , H3.3 was distributed in both the promoter and the body of active genes (Extended Data Fig. 5b ). The gene-bodyassociated H3.3 showed a strong co-occupancy with H3K36me3 (Fig. 3c) . Two-thirds of all the ZMYND11-bound genes overlapped with H3K36me3 and H3.3-co-occupied genes (P , 1 3 10 2465 ) ( Fig. 3c) , as also represented by a genome-browser view of the ChIP-seq signals ( Fig. 3d) . High ZMYND11 occupancies were observed in genes enriched with both H3K36me3 and H3.3, whereas ZMYND11 occupancies were much lower in genes only decorated with H3K36me3 or H3.3 ( Fig. 3e-g ). Depletion of ZMYND11 by short hairpin RNAs (shRNAs) drastically diminished the ChIP-seq signals (Extended Data Fig. 5c-g ), suggesting that the ChIP data obtained using our ZMYND11 antibody reflect the endogenous ZMYND11 chromatin-binding pattern.
ZMYND11 densities in gene bodies were directly correlated with H3K36me3 levels (Extended Data Fig. 6a ). We then asked whether ZMYND11 occupancy was H3K36me3 dependent. We found that ZMYND11 binding on target genes was reduced along with diminished H3K36me3 levels in the SETD2 (ref. .1 (h). H3 segment and key hydrogenbonding residues from ZMYND11 bromo-PWWP are depicted in ball-andstick mode. Cyan circle, water; blue dashed line, hydrogen bonds; curved brush, hydrophobic contact. i, ITC curves of ZMYND11 bromo-PWWP domains and the indicated point mutants with the H3.3K36me3 peptide.
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Extended Data Fig. 6b-d ), but not in the NSD2 (an H3K36me2 methyltransferase) 21 knockdown cells where the H3K36me3 levels remained largely unchanged (Extended Data Fig. 6e, f) . Furthermore, the H3.3K36me3 recognition-deficient mutants of ZMYND11 were severely impaired in binding on target genes ( Fig. 3i and Extended Data Fig. 6g, h ). Taken together, these results strongly suggest that ZMYND11 co-localizes with H3K36me3 and H3.3 in the gene body, and its occupancy requires the pre-deposition of trimethylation on H3.3K36.
To identify ZMYND11-regulated genes genome-wide, we performed RNA-seq analysis in U2OS cells. We found that 268 genes were upregulated and 370 genes downregulated upon ZMYND11 depletion ( Table 5 ). Gene ontology analysis showed that the upregulated genes in ZMYND11 knockdown cells were specifically enriched in small cell lung cancer and focal adhesion pathways; in contrast, the downregulated genes were not enriched in any pathways ( Fig. 4b and Supplementary Table 5 ). Ingenuity pathway analysis (IPA) of disease association of the upregulated genes also showed a high enrichment in cancer (Fig. 4b) . These data suggest that ZMYND11 has a role in both transcriptional repression and activation, but it specifically represses oncogene expression.
Because ZMYND11 is localized in the gene body, we postulated that ZMYND11 regulates gene expression at the transcription elongation rather than the initiation step. The gene body RNA polymerase II (Pol II) density correlates well with transcription elongation rate 22, 23 ; we therefore determined the changes of Pol II density upon ZMYND11 depletion. ZMYND11 occupancies were enriched in genes with high Pol II densities (P , 1 3 10 2401 ) (Extended Data Fig. 8a, b and Supplementary Table 6 ). Upon ZMYND11 depletion, we observed increased Pol II occupancy specifically on ZMYND11-repressed genes (Fig. 4c, d and Extended Data Fig. 8c) . Notably, only the amount of the intragenic Pol II, especially Pol II near the 39 end of the gene body, was markedly increased, whereas the promoter-associated Pol II remained largely unchanged (Fig. 4c, d ). Similar increases were also observed for the elongation-specific Pol II that is phosphorylated at serine 2 (S2P) 24 and the intragenic H3K36me3 levels ( Fig. 4c and Extended Data Fig. 8d, e) . The phenomenon of specific increase of Pol II in the gene body was further supported by the quantified Pol II travelling ratio 22 (Extended Data Fig. 8f ). Together, these data suggest that ZMYND11 occupancy correlates with Pol II density in the gene body, and ZMYND11 represses gene expression by preventing the transition of paused Pol II to elongation.
ZMYND11 is downregulated in several human cancers including breast cancer (Extended Data Fig. 9a ), indicating that ZMYND11 is a candidate tumour suppressor 25 . Overexpression of the wild-type ZMYND11 inhibited tumour cell growth, whereas the H3.3K36me3 binding-deficient mutants showed severe defects in suppressing cell proliferation and survival in both U2OS and the invasive MDA-MB 231 breast cancer cells ( Fig. 4e and Extended Data Fig. 9b-e) . Furthermore, in a mouse xenograft study using MDA-MB 231 cells, we found that compared with mice injected with control cells, tumour formation was strongly suppressed in mice injected with cells expressing wild-type ZMYND11, whereas the H3.3K36me3-binding deficient mutant W294A was severely impaired in suppressing tumour growth in vivo (Fig. 4f) . Interestingly, D307N, a missense mutation identified in patients with colon and rectum adenocarcinoma (Extended Data Fig. 9f ), diminished ZMYND11 binding to H3.3K36me3 ( Fig. 2i and Extended Data Fig. 9g-i) and its tumour suppressor function in mice (Fig. 4f) . Taken together, these results indicate that ZMYND11 suppresses phenotypes of cancer cells in a manner that depends on its H3.3K36me3-binding activity. Consistent RPS8  G6PD  HMGA1  KAP1  NFKB2  PCBP1  NFKBIA  ZNF8  ZNF558  ZNF625  ZNF530  ZNF551  ZNF773  ZNF468  ZNF557  MBLAC1  CDK5R2  CCR10  GADD45G  ADRB2  CRH  MMP28  KRTAP21 
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with these experimental results, low ZMYND11 expression levels in breast cancer patients correlate with worse disease-free survivals ( Fig. 4g and Extended Data 9j, k).
In summary, we have identified ZMYND11 as an H3.3-specific reader of H3K36me3. To our knowledge, it represents the first variantspecific reader of methylated histones. The combination of H3K36me3 and H3.3 establishes a unique epigenetic state that defines the genomic distribution of ZMYND11, offering a spatiotemporal control of gene expression for both normal and neoplastic growth. Because both H3K36me3 and H3.3 are deposited into the chromatin along with elongating Pol II, ZMYND11 is likely to be recruited to gene bodies only after one or several rounds of transcription when sufficient H3.3K36me3 is accumulated. We propose that, rather than as an on/off switch, ZMYND11 mainly functions in 'fine-tuning' gene expression by modulating Pol II elongation.
Our findings also emphasize the importance of the histone variant H3.3 in tumour suppression. Frequent mutations of the H3.3-encoding H3F3A gene have recently been identified in paediatric glioblastoma 26, 27 . Unlike the K27M mutation in a single copy of the H3.3-encoding gene that affects the global H3K27 methylation amounts, the G34V/R mutations only alter the H3K36me3 levels at certain genes 28, 29 . Interestingly, the G34V/R mutations impaired ZMYND11 binding to the H3.3K36me3 peptide (Extended data Fig. 9l ). It remains an open question whether disruption of the binding of ZMYND11, or other yet unknown H3.3K36me3 readers, has a physiological impact on the pathogenesis of paediatric glioblastoma.
METHODS SUMMARY
Peptide microarray and binding assays were performed in buffer containing 50 mM Tris-HCl 7.5, 300 or 200 mM NaCl, 0.1% NP-40 overnight followed by three washes. Crystallizations of bromo-PWWP and bromo-PWWP-peptide complexes were performed by the hanging-drop vapour diffusion method at 18 uC.
Diffraction data were collected at synchrotron beamlines under cryoconditions. The initial phase was solved by zinc single-wavelength anomalous dispersion . Tumour xenograft was performed by subcutaneously injecting 5 3 10 6 MDA-MB 231 cells into nude mice. Survival analyses were performed as described previously 30 .
Details are described in Methods.
Online Content Any additional Methods, Extended Data display items and Source Data are available in the online version of the paper; references unique to these sections appear only in the online paper. . Antihistone antibodies including anti-H3 (Ab1791), anti-H3K36me3 (Ab9050), antiH3K36me2 (Ab9049), anti-H3K4me3 (Ab8580) antibodies and anti-Pol II S2P were obtained from Abcam. Anti-Flag (M2) and anti-tubulin antibodies were from Sigma; anti-NSD2 was from Epicypher, anti-GST and anti-total Pol II antibodies were from Santa Cruz; and anti-MYC antibodies were from Cell Signaling. shRNA constructs were purchased from Sigma. shRNA sequences were as follows: ZMYND11: 59-GAAGGGAAATACCGAAGTTAT and 59-CCTGACAACTGGTTCTGTTAT; SETD2: 59-AGTAGTGCTTCCCGTTATAAA and TGATAGCCATGATAGTA TTAAC; NSD2: 59-CGGAAAGCCAAGTTCACCTTT. Peptide microarray and peptide pull-down assay. Peptide microarray and peptide pull-down assays were performed as described previously 32, 33 . Briefly, biotinylated histone peptides were printed in triplicate onto a streptavidin-coated slide (PolyAn) using a VersArray Compact Microarrayer (Bio-Rad). After a short blocking with biotin (Sigma), the slides were incubated with the GST-fused ZMYND11 PBP or other desired proteins in binding buffer (50 mM Tris-HCl 7.5, 300 mM NaCl, 0.1% NP-40, 1 mM PMSF, 20% fetal bovine serum) overnight at 4 uC with gentle agitation. After being washed with the same buffer, the slides were probed with an anti-GST primary antibody and then a fluorescein-conjugated secondary antibody and visualized using a GenePix 4000 scanner (Molecular Devices). For the peptide pull-down assays, 1 mg of biotinylated histone peptides with different modifications were incubated with 1-2 mg of GST-fused proteins in binding buffer (50 mM Tris-HCl 7.5, 300 mM NaCl, 0.1% NP-40, 1 mM PMSF) overnight. Streptavidin beads (Amersham) were added to the mixture, and the mixture was incubated for 1 h with rotation. The beads were then washed three times and analysed using SDS-PAGE and western blotting. To preserve the weak binding between ZMYND11 PBP and histone H3.1K36me3, mild buffer (50 mM Tris-HCl 7.5, 200 mM NaCl, 0.05% NP-40, 1 mM PMSF) was used for binding and washes. Other steps are essentially the same as described above. Histone binding, nucleosome preparation and electrophoretic mobility shift assay (EMSA). Full-length histone pull-down assays were performed as described previously 34 . Briefly, 10 mg of full-length histones purified from calf thymus (Wormington) were incubated with 25 mg of recombinant proteins for 4 h to overnight in a binding solution containing 50 mM Tris pH 7.5, 300 mM NaCl and 0.05% NP-40. Glutathione Sepharose 4B beads (Amersham) were added to the solution for 1 h. The beads were then washed six times and bound histones were detected using western blot analysis.
Recombinant Xenopus histones were individually purified and reconstituted into histone octamers using a previously described protocol 35 . All histone H3K36 methylated histones were prepared using the methyl-lysine analogue (MLA) approach 36 . The chemical reactions result in almost all lysines being converted to methylation mimics, as was confirmed by mass spectrometry analysis and western blotting.
EMSA for nucleosome binding was as described previously 35 . EMSA reactions were performed in a 15-ml system containing 10 mM HEPES pH 7.8, 50 mM KCl, 4 mM MgCl 2 , 5 mM DTT, 0.25 mg ml 21 BSA, 5% glycerol and 0.1 mM PMSF. Primer pairs (59-ACAGGATGTATATATCTGACACGTGCCTGG-39) and (59-TGACCAAGGAAAGCATGATTCTTCACAC-39) were designed to generate the 216 base-pair mono-nucleosome probe by using plasmid pBL386 as template followed by P32 exchange reaction for labelling. MLA-nucleosomes and indicated proteins were pre-mixed in EMSA buffer and incubated at 30 uC for 1 h. Then, the total reactions were directly loaded onto a 4% native polyacrylamide gel (37.5:1) in 0.3 3 TBE. Electrophoresis was performed at 4 uC for 3.5 h. Crystallization, data collection and structural determination. ZMYND11 bromo-PWWP domains were cloned into pET28 vector and expressed with amino (N)-terminal His-tag in Escherichia coli strain BL21 (DE3) (Novagen) in the presence of 0.5 mM IPTG and 50 mM ZnCl 2 . Overnight-induced cells were collected by centrifugation and re-suspended in lysis buffer: 300 mM NaCl, 50 mM Na 2 HPO 4 , 5 mM imidazole, pH 7.0 and 1 mM PMSF. Then cells were lysed with an Emulsiflex C3 (Avestin) high-pressure homogenizer. After centrifugation at 16,770g, the supernatant was applied to a HisTrap column (GE Healthcare), and the protein was eluted with a linear imidazole gradient from 50 to 500 mM. The resultant protein was further purified by cation-exchange chromatography using a HiTrap SP column (GE Healthcare). The peaks eluted under the buffer condition 600 mM NaCl, 50 mM Na 2 HPO 4 , pH 7.0 were pooled and concentrated to approximately 20 mg ml -1 . D234A/E236A double mutant bromo-PWWP (BP DM ) was generated by a QuickChange site-direct mutagenesis kit (Stratagene), expressed and purified using essentially the same procedure as for the wild-type protein.
Crystallization was performed by the hanging-drop vapour diffusion method under 18 uC by mixing equal volumes (1-2 ml) of protein and reservoir solution. Crystals were briefly soaked in a cryo-protectant composed of reservoir solution supplemented with 20% glycerol, and were flash frozen in liquid nitrogen for data collection at 100 K. The wild-type free bromo-PWWP data set was collected at beamline 1W2B at the Beijing Synchrotron Radiation Facility at 1.2825 Å , the zinc absorption edge. Complex data sets were collected at beamline BL17U at the Shanghai Synchrotron Radiation Facility at 0.9793 Å for the H3.3K36me3 complex and at 1.0076 Å for the H3.1K36me3 complex. All data were indexed, integrated and merged using the HKL2000 software package 37 . Data collection statistics are shown in Extended Data Table 1 .
The phase of free bromo-PWWP was solved by the zinc single-wavelength anomalous dispersion method using PHENIX software 38 . The BP DM -H3 peptide complex structures were solved by molecular replacement using MOLREP 39 with the free bromo-PWWP structure as search model. All structures were refined using PHENIX 23 , with iterative manual model building using COOT 40 . Model geometry was analysed with PROCHECK 41 . Ramachandran plot analysis showed 92.6%, 95.0% and 93.7% residues in most favoured regions, and 7.4%, 5.0% and 6.3% residues in allowed regions, for free bromo-PWWP, BP DM -H3.3 and BP DM -H3.1 complexes, respectively. Detailed structural refinement statistics are shown in Extended Data Table 1 . All structural figures were created using PYMOL (http:// www.pymol.org/). Circular dichroism spectroscopy. Purified proteins were prepared in buffer 25 mM Na 2 HPO 4 pH 7.0, 500 mM (NH 4 ) 2 SO 4 by overnight dialysis. Circular dichroism spectra were recorded at a protein concentration of 0.1 mg ml -1 under 15 uC using an Applied Photo-physics Pistar p-180 spectropolarimeter with a 1 mm path-length cell and a bandwidth of 3.0 nm. Spectra were scanned from 190 to 260 nm at an interval of 1 nm and were repeated three times. Each reported circular dichroism curve was the average of three scans after the subtraction of buffer control. ITC and biolayer interferometry assays. For ITC measurement, synthetic histone H3.3 K36me3 and H3.1 K36me3 peptides (SciLight Biotechnology) and the wild-type and mutant bromo-PWWP or PBP proteins were extensively dialysed against ITC buffer: 0.5 M (NH 4 ) 2 SO 4 and 25 mM Na 2 HPO 4 , pH 7.0. Protein and peptide concentrations were measured based on their respective ultraviolet absorption at 280 nm. The titration was performed using a MicroCal iTC200 system (GE Healthcare) at 15 uC. The use of high salt (0.5 M (NH 4 ) 2 SO 4 ) and low temperature (15 uC) is critical to prevent protein precipitation during the ITC titration. Each ITC titration consisted of 17 successive injections with 0.4 ml for the first and 2.42 ml for the rest. Usually, H3 peptides at 1.5 mM were titrated into bromo-PWWP or PBP at 0.07-0.1 mM. Corresponding 'peptide to buffer' or 'buffer to protein' controls were performed for background correction. The resultant ITC curves were processed using Origin 7.0 software (OriginLab) according to the 'One Set of Sites' fitting model. Owing to the low Wiseman c value of most titrations, the stoichiometry (n value) was fixed at 1 for valid curve fitting 42 . GST and GST-tagged ZMYND11 bromo-PWWP proteins were immobilized onto anti-GST antibody-coated biosensors (Fortebio, Pall Life Sciences). After being washed with binding buffer (25 mM NaH 2 PO4 pH7.0, 150 mM KCl and 2 mM MgCl 2 ), the sensors were dipped into binding buffers containing methylated or unmethylated double-strand DNA at various concentrations for 5 min for complete association followed by 5 min disassociation in binding buffer without DNA. Kinetics were recorded using Octet RED96 (Fortebio, Pall Life Sciences) at 1,000 r.p.m. vibration at 25 uC. Steady-state analysis used the following equation with Octet data analysis 7.0: response 5 R max 3 concentration/(K d 1 concentration), where R max is the maximum binding signal and K d is the dissociation constant. DNA sequences (derived from the Widom 601 sequence 43 ) used in these assays were as follows: unmethylated dsDNA, 59-CAGCTGAACATCGCTTTTGATG-39; methylated dsDNA, 59-CAGCTGAACAT[5medC]GCTTTTGATG-39. Cell culture, viral transduction and RNA interference. Human U2OS, HEK 293T and MDA-MB-231 cells (ATCC) were maintained in DMEM (Cellgro) supplemented with 10% fetal bovine serum (Sigma). Retroviral transduction was performed as described previously 32 . Briefly, 293T cells were co-transfected with pVPack-VSV-G, pVPack-GP (Stratagene) and pBABE-Flag-ZMYND11, LETTER RESEARCH pQCXIP-ZMYND11 or control vectors, and viral supernatants were collected after 48 h. For lentiviral shRNA packaging, 293T cells were co-transfected with pMD2.G, pPAX2 (Addgene) and pLKO-shRNA constructs. For infections, the cells were incubated with viral supernatants in the presence of 8 mg ml 21 polybrene; after 48 h, infected cells were selected with puromycin (2 mg ml
21
). Cell proliferation and colony formation assays were performed as previously described 31 . Affinity purification, immunoprecipitation and co-immunoprecipitation. Nuclear extracts were prepared as described previously 31, 44 . The nuclear extracts were diluted with low salt buffer (20 mM Tris-HCl pH 8.0, 50 mM NaCl, 0.2% Triton X-100, 10% glycerol, 1 mM DTT) to a final NaCl concentration of 120 mM. Two hundred microlitres of 50% M2 Flag-agarose beads were added to the nuclear extracts and incubated at 4 uC overnight. The beads were then washed with wash buffer (20 mM Tris-HCl pH8.0, 250 or 500 mM KCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 10% glycerol, 0.2 mM PMSF, 1 mM DTT and protease inhibitors) three to six times, and eluted with 300 ml of 0.3 mg ml 21 Flag peptide in dialysis buffer (20 mM Tris-HCl pH 7.4, 150 mM NaCl, 1 mM DTT) at 4 uC for 4 h three times. The bound proteins were separated in SDS-PAGE and sent for mass spectrometric analysis. Liquid chromatography/tandem mass spectrometry was done at the Harvard Taplin MS core facility and at the University of Texas Medical Branch MS core facility.
For immunoprecipitation or co-immunoprecipitation experiments, cells were lysed in cell lysis buffer containing 50 mM Tris-HCl pH 7.4, 250 mM NaCl, 0.5% Triton X-100, 10% glycerol, 1 mM DTT and a complete protease inhibitor tablet (Roche). Antibodies conjugated with protein A/G beads (Millipore) or anti-Flag M2-conjugated agarose beads (Sigma) were incubated with lysates overnight at 4 uC. The beads were then washed three to six times with cell lysis buffer, and the bound proteins were eluted in SDS buffer and analysed using western blotting. ChIP and ChIP-seq analysis. ChIP analysis was essentially as previously described 32 . Briefly, cells were crosslinked with 1% formaldehyde for 10 min at room temperature, and the reaction was stopped with 125 mM glycine. Nuclei were isolated by re-suspending the cells in swelling buffer containing 5 mM PIPES pH 8.0, 85 mM KCl, 1% NP-40 and a complete protease inhibitor for 20 min at 4 uC. The isolated nuclei were re-suspended in nuclei lysis buffer (50 mM Tris pH 8.0, 10 mM EDTA, 1% SDS) and sonicated using a Bioruptor Sonicator (Diagenode). Samples were immunoprecipitated with the appropriate antibodies overnight at 4 uC. After incubation with Staph A cells for 15 min, immunoprecipitates were washed twice with dialysis buffer (50 mM Tris pH 8.0, 2 mM EDTA, 0.2% Sarkosyl) and four times with immunoprecipitation wash buffer (100 mM Tris pH 8.0, 500 mM LiCl, 1% NP-40 and 1% deoxycholic acid sodium salt). After reverse crosslinking was performed, DNA was eluted, purified using a PCR purification kit (Qiagene) and subjected to qPCR on the ABI 7500-FAST System using the Power SYBR Green PCR Master Mix (Applied Biosystems).
ChIP-seq was done essentially as described above, except using proteinA/G beads instead of Staph A cells for immunoprecipitation. Samples were sequenced using the Illumina Solexa Hiseq 2000. The raw reads were mapped to human reference genome NCBI 36 (hg18) by Solexa data processing pipeline, allowing up to two mismatches. The genome ChIP-seq profiles were generated using MACS 1.3.6 (ref. 45 ) with only unique mapped reads. Clonal reads were automatically removed by MACS. The ChIP-seq profiles were normalized to 10,000,000 total tag numbers, and peaks were called at P # 1 3 10
28
. For ZMYND11 and H3K36me3 ChIP samples, peaks were annotated by REFSEQ genes that had overlaps within TSS to TTS. For Pol II samples, peaks were annotated by REFSEQ genes that had overlaps within TSS-3K to TTS. The distribution statistics of the ChIP-seq peaks were performed using the Cis-regulatory element annotation system 46 . All ChIPseq data are summarized in Supplementary Table 7 . Reverse transcription PCR, northern blotting, qPCR and RNA-seq analysis. Reverse transcription PCR and real-time PCR were performed as previously described 32 . Total RNA was prepared using the RNeasy Plus kit (Qiagen) and reverse-transcribed using the First Strand Synthesis kit (Invitrogen). Northern blotting and hybridization used a Northern Max-Gly kit (Invitrogen) following the manufacturer's instructions. Twenty micrograms of total RNA were used for each lane. qPCR was performed on the ABI 7500-FAST Sequence Detection System using the Power SYBR Green PCR Master Mix (Applied Biosystems). Gene expressions were calculated following normalization to GAPDH amounts using the comparative Ct (cycle threshold) method. Primer sequences are available upon request.
RNA-seq samples were sequenced using the Illumina Hiseq 2000, and raw reads were mapped to human reference genome (hg18) and transcriptome using the RNA-Seq unified mapper 47 . The expression levels of ZMYND11 KD and control expressed as reads per kilobase per million were compared using EdgeR. Genes with fewer than five reads per kilobase per million in both the ZMYND11 KD and control samples were removed. Genes with a fold change $ 1.5 were selected as differential genes. Gene ontology analysis used the DAVID Bioinformatics Resource 6.7 (ref. 48) . Expression signatures and survival analysis. Survival analyses were performed as described previously 30 . The database consisting of 13 breast cancer expression profiling data sets from Gene Expression Omnibus was used in the 'consolidated' survival analysis through the Kaplan-Meier plotter central server. Data were loaded into the R statistical environment, where calculations were performed. The package 'survival' was used to calculate and plot Kaplan-Meier survival curves, and the number-at-risk was indicated below the main plot. P values were calculated using the log-rank test. For data validation, independent analysis of Gene Expression Omnibus data sets GSE6532 and GSE7390 were performed as previously described 49 . Tumour xenograft. All animal studies were in compliance with ethical regulations at the University of Texas MD Anderson Cancer Center. Female athymic nude mice (age 6-8 weeks) were obtained from the National Cancer Institute at Frederick and animals were housed under pathogen-free conditions. Five million MDA-MB 231 cells stably expressing control pQCXIP vector, wild-type ZMYND11 or mutants were suspended in 100 ml of serum-free DMEM and injected subcutaneously into the mice. The growth of tumours was monitored by weekly examination until the largest tumour reached tumour burden. Tumour sizes were measured using a calliper, and tumour volume was calculated according to the following equation: tumour volume (mm 3 ) 5 (length (mm) 3 width 2 (mm 2 )) 3 0.5. Representative data were obtained from five mice per experimental group. Statistical analyses were performed with one-way repeated-measures analysis of variance.
